You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
CI 966 hydrochloride
Biological Activity for CI 966 hydrochloride
CI 966 hydrochloride is a selective inhibitor of the GABA transporter GAT-1 (IC50 values are 0.26 and 1.2 μM at cloned human and rat GAT-1 respectively). Displays over 200-fold selectivity over GAT-2 and GAT-3. Centrally active upon systemic administration in vivo. Anticonvulsive and neuroprotective.
Compound Libraries for CI 966 hydrochloride
Technical Data for CI 966 hydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CI 966 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CI 966 hydrochloride
The following data is based on the product molecular weight 509.87. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.96 mL||9.81 mL||19.61 mL|
|5 mM||0.39 mL||1.96 mL||3.92 mL|
|10 mM||0.2 mL||0.98 mL||1.96 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
Product Datasheets for CI 966 hydrochloride
References for CI 966 hydrochloride
References are publications that support the biological activity of the product.
Borden et al (1994) Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219 PMID: 7851497
Ebert et al (1990) Systemic CI-966, a new gamma-aminobutyric acid uptake blocker, enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ. Can.J.Physiol.Pharmacol. 68 1194 PMID: 2276082
Radulovic et al (1993) Pharmacokinetics, mass balance, and induction potential of novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. Pharm.Res. 10 1442 PMID: 8272405
If you know of a relevant reference for CI 966 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: CI 966 hydrochloride, CI 966 hydrochloride supplier, Selective, inhibitors, inhibits, GAT-1, GABA, Transporters, Monoamine, Neurotransmitter, CI966, hydrochloride, 1296, Tocris Bioscience
Citations for CI 966 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for CI 966 hydrochloride. Do you know of a great paper that uses CI 966 hydrochloride from Tocris? Please let us know.
Reviews for CI 966 hydrochloride
There are currently no reviews for this product. Be the first to review CI 966 hydrochloride and earn rewards!
Have you used CI 966 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.